Anaptys has cash, cash equivalents and investments greater than $420M as of December 31, 2024, and anticipates receipt of a $75M commercial sales milestone payment from GSK in 2025 or 2026. Notwithstanding the potential full execution of the Stock Repurchase Plan, the Company reiterates its previous cash runway guidance through year-end 2027 to execute its research and development plan, excluding potential future royalties from its GSK immuno-oncology financial collaboration.
Claim 30% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ANAB:
- Wells Fargo Predicts Up to ~440% Rally for These 2 ‘Strong Buy’ Stocks
- AnaptysBio price target raised to $42 from $36 at JPMorgan
- Cautious Hold Rating on AnaptysBio Amid Mixed Clinical Trial Results and Strategic Uncertainties
- AnaptysBio price target raised to $52 from $36 at Guggenheim
- AnaptysBio: Strong Financial Performance and Promising Pipeline Drive Buy Rating